Recce Pharmaceuticals (RCE) Stock Overview
Recce Pharmaceuticals Ltd, discovers, develops, and commercializes synthetic anti–infectives in Australia, the United Kingdom, and the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
RCE Community Fair Values
Create NarrativeSee what 6 others think this stock is worth. Follow their fair value or set your own to get alerts.
Recce Pharmaceuticals Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.40 |
| 52 Week High | AU$0.73 |
| 52 Week Low | AU$0.28 |
| Beta | 0.39 |
| 1 Month Change | -29.82% |
| 3 Month Change | -15.79% |
| 1 Year Change | 29.03% |
| 3 Year Change | -36.00% |
| 5 Year Change | -59.18% |
| Change since IPO | 33.33% |
Recent News & Updates
Recent updates
Shareholder Returns
| RCE | AU Pharmaceuticals | AU Market | |
|---|---|---|---|
| 7D | -16.7% | -6.5% | -0.9% |
| 1Y | 29.0% | -27.2% | 2.3% |
Return vs Industry: RCE exceeded the Australian Pharmaceuticals industry which returned -21.6% over the past year.
Return vs Market: RCE exceeded the Australian Market which returned 1.8% over the past year.
Price Volatility
| RCE volatility | |
|---|---|
| RCE Average Weekly Movement | 9.4% |
| Pharmaceuticals Industry Average Movement | 9.5% |
| Market Average Movement | 9.9% |
| 10% most volatile stocks in AU Market | 17.1% |
| 10% least volatile stocks in AU Market | 4.0% |
Stable Share Price: RCE has not had significant price volatility in the past 3 months compared to the Australian market.
Volatility Over Time: RCE's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | n/a | James Graham | www.recce.com.au |
Recce Pharmaceuticals Ltd, discovers, develops, and commercializes synthetic anti–infectives in Australia, the United Kingdom, and the United States. The company’s lead candidate is RECCE 327 (R327) for the treatment of life-threatening bacterial infections. In addition, its product pipeline comprises R327 Intravenous, which is in Phase I and Phase I/II clinical trial for the treatment of urinary tract infections/urosepsis; and R327 Topical Gel, which is Phase II clinical trial for the treatment of acute bacterial skin and skin structure infections, as well as is in Phase I/II clinical trials for topical wound infections and diabetic foot infections.
Recce Pharmaceuticals Ltd Fundamentals Summary
| RCE fundamental statistics | |
|---|---|
| Market cap | AU$115.67m |
| Earnings (TTM) | -AU$30.25m |
| Revenue (TTM) | AU$974.56k |
Is RCE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RCE income statement (TTM) | |
|---|---|
| Revenue | AU$974.56k |
| Cost of Revenue | AU$12.15m |
| Gross Profit | -AU$11.18m |
| Other Expenses | AU$19.07m |
| Earnings | -AU$30.25m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.10 |
| Gross Margin | -1,147.19% |
| Net Profit Margin | -3,104.24% |
| Debt/Equity Ratio | 0% |
How did RCE perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/26 09:51 |
| End of Day Share Price | 2026/06/26 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Recce Pharmaceuticals Ltd is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jyoti Prakash | Edison Investment Research |
| Chris Kallos | MST Financial Services Pty Limited |